nVerses Capital’s Moderna MRNA Stock Holding History

nVerses Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,500	Closed	-$301K	–	541
2024 Q3	$301K	Buy	+4,500	New	+$413K	0.14%	240

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

nVerses Capital's MRNA Position: Q4 2024 in Review

nVerses Capital sold out of Moderna (MRNA) in Q4 2024, closing a stake of 4,500 shares — an estimated $301K sold.

nVerses Capital first reported a position in MRNA in Q3 2024 and held it in 1 quarter. The position peaked at $301K in Q3 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

nVerses Capital reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 4,500 Moderna shares in Q4 2024, an estimated $301K.
nVerses Capital first reported a position in Moderna in Q3 2024 and held it in 1 quarter.
nVerses Capital's Moderna position peaked at $301K in Q3 2024.
745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.